※ 引述《phosita (phosita)》之銘言：
: ASCO可不是個隨隨便便的單位，
: 如果實驗結果沒有顯著的意義，
: 要登上ASCO可說是不可能的。
: 如果ASCO接受論文，那不就代表皓鼎的實驗有顯著的意義？
說到這個倒是想起一個8年前發生的事件,
故事也涉及收購optimer的merck藥廠
Drugmakers accused of delaying ENHANCE data
http://tinyurl.com/hj2urvv
http://www.thepharmaletter.com/article/drugmakers-accused-of-delaying-enhance-data
________________________________________________________
In the days after results from the ENHANCE study were announced
the share price of both companies suffered. On January 17, shares
in S-P fell 8% and were 22% down over the course of the week. Shares
in Merck dropped 6% on the same day and 9% over the week but the firm
has other big earners in its portfolio and is less exposed, while
Vytorin is S-P's lead drug.
________________________________________________________
ENHANCE study是一個降膽固醇藥物的研究, April 2006就已完成
放到2008年1月才發布結果,當周S-P股價跌了22%, merck也跌了9%
該研究的論文最後於2008年4月刊登在內科頂尖期刊的NEJM
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
http://www.nejm.org/doi/full/10.1056/NEJMoa0800742
N Engl J Med 2008; 358:1431-1443 April 3, 2008
________________________________________________________
Conclusions
In patients with familial hypercholesterolemia, combined therapy
with ezetimibe and simvastatin did not result in a significant
difference in changes in intima–media thickness, as compared
with simvastatin alone, despite decreases in levels of LDL cholesterol
and C-reactive protein. (ClinicalTrials.gov number, NCT00552097.)
________________________________________________________
請問這算是NEJM給他平反嗎? XDD